Source:http://linkedlifedata.com/resource/pubmed/id/20014009
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2010-2-22
|
pubmed:abstractText |
Alzheimer's disease (AD) is characterized by the deposition of amyloid-beta peptide (Abeta) and the formation of neurofibrillary tangles. Transplantation of bone marrow-derived mesenchymal stem cells (BM-MSCs) has been suggested as a potential therapeutic approach to prevent various neurodegenerative disorders, including AD. However, the actual therapeutic impact of BM-MSCs and their mechanism of action in AD have not yet been ascertained. The aim of this study was therefore to evaluate the therapeutic effect of BM-MSC transplantation on the neuropathology and memory deficits in amyloid precursor protein (APP) and presenilin one (PS1) double-transgenic mice. Here we show that intracerebral transplantation of BM-MSCs into APP/PS1 mice significantly reduced amyloid beta-peptide (Abeta) deposition. Interestingly, these effects were associated with restoration of defective microglial function, as evidenced by increased Abeta-degrading factors, decreased inflammatory responses, and elevation of alternatively activated microglial markers. Furthermore, APP/PS1 mice treated with BM-MSCs had decreased tau hyperphosphorylation and improved cognitive function. In conclusion, BM-MSCs can modulate immune/inflammatory responses in AD mice, ameliorate their pathophysiology, and improve the cognitive decline associated with Abeta deposits. These results demonstrate that BM-MSCs are a potential new therapeutic agent for AD.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
1549-4918
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
28
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
329-43
|
pubmed:dateRevised |
2010-11-18
|
pubmed:meshHeading |
pubmed-meshheading:20014009-Alzheimer Disease,
pubmed-meshheading:20014009-Amyloid beta-Peptides,
pubmed-meshheading:20014009-Animals,
pubmed-meshheading:20014009-Blotting, Western,
pubmed-meshheading:20014009-Bone Marrow Cells,
pubmed-meshheading:20014009-Cells, Cultured,
pubmed-meshheading:20014009-Enzyme-Linked Immunosorbent Assay,
pubmed-meshheading:20014009-Maze Learning,
pubmed-meshheading:20014009-Memory Disorders,
pubmed-meshheading:20014009-Mesenchymal Stem Cell Transplantation,
pubmed-meshheading:20014009-Mice,
pubmed-meshheading:20014009-Mice, Transgenic,
pubmed-meshheading:20014009-Presenilin-1
|
pubmed:year |
2010
|
pubmed:articleTitle |
Intracerebral transplantation of bone marrow-derived mesenchymal stem cells reduces amyloid-beta deposition and rescues memory deficits in Alzheimer's disease mice by modulation of immune responses.
|
pubmed:affiliation |
Stem Cell Neuroplasticity Research Group, Kyungpook National University, Daegu, Korea.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|